

## Role of HbA1c and microalbuminuria in diabetic-hypertensive individuals: An index for the diabetic nephropathy

P. Srilakshmi<sup>1\*</sup>, Rama Krishna Reddy Y. V<sup>2</sup>, Prathibha Bharathi K<sup>3</sup>, K Rambabu<sup>4</sup>

<sup>1</sup>Associate Professor, <sup>2</sup>Assistant Professor, <sup>3</sup>Consultant Biochemist, <sup>4</sup>Professor, Dept. of Biochemistry, <sup>1,2,4</sup>Mamata Medical College, Khammam, Telangana, <sup>3</sup>Apollo Lab Services, Nellore, Andhra Pradesh, India

\*Corresponding Author: P. Srilakshmi

Email: sri.biochemistry@gmail.com

Received: 24<sup>th</sup> September, 2018

Accepted: 1<sup>st</sup> November, 2018

### Abstract

**Introduction:** The present study was carried out to assess the influence of advanced glycosylation end products, microalbuminuria, and hypertension in development of nephropathy in diabetic-hypertensive individuals. Microalbuminuria has been shown to be a risk factor for nephropathy in patients with type 2 diabetes with uncontrolled glycemic index. In this study, we aimed to explore the association advanced glycosylated end products between microalbuminuria and other risk factors in the development of diabetic nephropathy in diabetic-hypertensive individuals.

**Materials and Methods:** A total of 131 individuals were randomly recruited in the study and were segregated into three groups. Group-I is normal (n=50) and group-II contains control DM (n=22) and group-III contains uncontrolled DM (n=59). Medical records were used to collect data of age, SBP, DBP and history of diabetes, hypertension. Blood samples were collected to estimate FBS, PPBS, glycosylated hemoglobin (HbA1C), and urine for estimation the urinary albumin.

**Result:** The FBS, PPBS, SBP has shown a significant rise between the controls and uncontrolled diabetes, where as DBP has show significant rise in the controlled diabetes in caparison to control group. Microalbuminuria and HbA1c has shown a significant rise in control diabetes and uncontrolled diabetes group when compared with control group. Microalbuminuria has shown a significant correlation with SBP, FBS, PPBS and HbA1c. ROC analysis indicates HbA1c and microalbuminuria are good markers for diabetic nephropathy.

**Conclusion:** Increased levels of microalbuminuria and advanced glycosylated end products will increase the compliance of diabetic-hypertensive individuals for developing the nephropathy.

**Keywords:** Diabetes, Glycated hemoglobin, Microalbuminuria.

### Introduction

With epidemiological, demographic, lifestyle and nutrition transition, non-communicable diseases like DM, HTN are increasing in India. Diabetic patients in developing countries like India are even more vulnerable to develop the microvascular complications of diabetes, including diabetic nephropathy and that too at an early age of life.<sup>1</sup>

Studies of Roberto Pedrinelli et al<sup>2</sup> says that, high blood pressure when transmitted to renal glomeruli, it might increase the glomerular ultrafiltration of albumin. Hypertension may increase capillary pressure and acute elevation in systemic perfusion pressure may accelerate hyperfiltration. The transcapillary macromolecular transport and might damage each of several different pathways, such as diffusion through endothelial cell membranes, passage via intercellular junctions, transendothelial channels of organs and tissues with highly different permeability, as well the surface area products, which alters systemic capillary permeability in essential hypertension.<sup>3</sup>

Microalbuminuria is considered to be an early stage of diabetic nephropathy, which is the leading cause of end stage renal disease worldwide.<sup>4,5</sup> It is the primary sign of renal predicting overt nephropathy.<sup>6</sup> Hence urine albumin is used as a very sensitive prognostic marker explicit nephropathy in patients with diabetes.<sup>7</sup> Monitoring levels of microalbuminuria and other risk factors associated with this condition will makes an importance in preventing or postpone overt nephropathy.<sup>1</sup>

In this present study, we aimed to explore the association of advanced glycosylation end products (HbA1c) between microalbuminuria in diabetic-hypertensive individuals in the development of diabetic nephropathy.

### Materials and Methods

The study was carried out with the patients attending to the out patients departments for health check up's at Apollo speciality Hospital, Nellore. A total of 131 individuals were randomly recruited in the study and were segregated into three groups. Group-I is Normal (n=50) and group-II contains control DM (n=22) and group-III contains uncontrolled DM (n=59). Informed consent were obtained from the individuals. Study was cleared by the institutional ethical clearance. Medical records were used to collect data like age, SBP, DBP and history of diabetes, hypertension. Blood samples were collected after 12 hours overnight fasting to analyze FBS, PPBS, using fully automated chemistry analyzer (Iris Diuri-400) whereas urinary albumin, HbA1C are estimated using immunoturbidometric kit method (DiaLab). Statistical work was done using SPSS-20.0 software. p value was considered significant at  $\leq 0.05$  level.

### Results

The FBS, PPBS, SBP has shown a significant rise between the controls and uncontrolled diabetes, where as DBP has shown significant rise in the controlled diabetes in caparison to control group. Microalbuminuria and HbA1c has

shown a significant rise in control diabetes and uncontrolled diabetes group when compared with control group (Table 1). HbA1c has shown a significant correlation with SBP, DBP, FBS, PPBS and Microalbuminuria with r values 0.744, 0.231, 0.708, 0.810 respectively. Microalbumin has shown a significant correlation with FBS, PPBS and HbA1c, SBP

with r values 0.211, 0.333, 0.398, 0.197 respectively (Table 2). ROC analysis indicates HbA1c and Microalbuminuria are good markers for diabetic hypertension with area under curve values (1.0, 0.680) with cut-off values (9.45, 429) respectively (Table 3).

**Table 1: Comparison of different parameters between the control and study groups**

Variable(s)	Normal (n=50) Group-I	Control DM (n=22) Group-II	Uncontrolled DM (n=59) Group-III	Significance Between Normal and study group
Age (years)	49.3±9.6	55.33±15.1	53.11±11.8	NS
Gender	Males	12	40	--
	Females	20	19	
Microalb mg/lit	16.04±4.1	121.82±50.6	131.75±65.1	Sig Group II & III
FBS mg/dl	91.35±8.29	109.92±18.08	156.26±58.0	Sig Group III
PPBS mg/dl	126.28±10.03	152.09±41.52	240.14±60.21	Sig Group III
HbA1c %	5.10±0.27	6.90±1.40	7.89±1.03	Sig Group II & III
SBP mmHg	122.02±8.95	124.82±11.7	151.08±18.2	Sig Group III
DBP mmHg	79.18±24.4	68.96±26.5	82.01±19.8	Sig Group II

Note: p value was considered significant at <0.05.

**Table 2: Correlation between different parameters**

Variable(s)	Micro Albumin	HbA1c
Age	0.94	0.189*
Microalb	1	0.398**
FBS	0.211*	0.708**
PPBS	0.333**	0.810**
HbA1c	0.398**	1
SBP	0.197*	0.744**
DBP	0.115	0.231**

Note: \* significance at 0.05 level; \*\* significance at 0.01 level.

**Table 3: ROC curve analysis**

Test variable(s)	Sensitivity	Specificity	Area Under Curve	Asymptotic 95% Confidence Interval		Cut-off Value
				Lower Bound	Upper bound	
Microalb mg/lit	0.051	0.972	0.647	0.680	0.855	429
HbA1c %	0.085	1.000	1.000	1.000	1.000	9.45

## Discussion

Significant rise in the FBS and PPBS levels in conjunction with microalbuminuria and HbA1c in both study groups indicates the formation of the AGE products, which will be the risk factor for the development of secondary complication in the diabetes. The significant rise of the SBP and micro albumin in both study groups indicates the future risk for the development of the nephropathy.<sup>8</sup>

Microalbuminuria an early sensitive marker in life of the altered cardio metabolic milieu that is associated with susceptibility in individual with CV disease in prediabetes and prehypertension. It is therefore an ideal target for early-primary prevention using CV-protective therapy regimens.<sup>9</sup> Albuminuria shown to be closely associated with salt intake as well as blood pressure.<sup>10</sup>

In our correlation study between the microalbuminuria and SBP has shown a significant correlation, which signifies the role of hypertension in diabetes influencing the glomerular ultrafiltration of albumin. In general, mainly SBP and to a lesser extent pulse pressure, is a major determinant for albuminuria. In fact, albuminuria remains almost unaltered with SBP within the normal range. In contrast, the response of the left ventricle to SBP is linear within the whole range of SBP. Some factors such as, use oral contraception in women and impaired glucose tolerance were shown to influence microalbuminuria.<sup>11</sup> Studies of Cohen MP et al, has found some other factors that impinge on glomerular permeability by modifying cytokines and affecting permeability. Increased amounts of glycated albumin reduce glomerular nephrin and increase vascular endothelial growth factor.<sup>12</sup> In addition to above factors, increase sodium intake

and intraglomerular pressure, high protein intake other wisely, poorly controlled blood pressure increase glomerular permeability in diabetes and, hence, micro albuminuria is observed.<sup>13</sup>

The microalbumin has also shown significant correlation with FBS, PPBS and HbA1c which shows the effect of glycemic index on glomerular membrane our study is correlated with the studies of, Ishibashi Y et al, and Tourigny A et al, reported that, albumin is glycated in individuals with diabetes, and forms advanced glycation end products, which in turn leads to production of reactive oxygen species, and other cellular toxins which will leads to vascular injury. The effect of pressor hormones, such as angiotensin-II will magnify the injury, resulting in a earlier progression of vascular injury. Which will direct the injury to the vascular smooth muscle cells, endothelial cells, and visceral epithelial cells of the glomerular capillary wall membrane as well as influencing the proximal tubular, and epithelial cells of basement membrane of nephron.<sup>12,14,15</sup>

Our study – HbA1c and Micro albuminuria has shown more area under curve which shows to be a good biomarkers for glycemic index and as well as glomerular capillary wall membrane permeability. Patel V et al reported that micro albuminuria may be most sensitive indicator to diagnose incipient diabetic nephropathy.<sup>16</sup>

## Conclusion

It is clear now that both the increased glycemic index forms advanced glycation end products and generates reactive oxygen species which will leads to vascular injury and the rise in systolic blood pressure will also influence glomerular permeability by modifying cytokines production that affect permeability. So both hypertension and uncontrolled blood sugar levels influence the development of nephropathy.

**Acknowledgements:** Nil.

**Conflict of Interest:** None.

## References

1. Dharamveer Yadav, Bhawani Kochar, Ankur Mathur, and Arun Chougale. Prevalence of Microalbuminuria in Type - 2 Diabetes Mellitus: A hospital based study. *Int J Res Grant* 2017;5(12):217-222.
2. Roberto Pedrinelli, Giuseppe Penno, Giulia Dell'Omo, Simona Bandinelli, Davide Giorgi, Vitantonio Di Bello. Microalbuminuria and transcapillary albumin leakage in essential hypertension. *Hypertension* 1999;34:491-495.
3. Sharan Badiger, Prema T. Akkasaligar, Sandeep HM and Biradar MS. Microalbuminuria in Essential Hypertension. *Int J Med Health Sci* 2011;5(12):716-720.
4. US Renal Data System. Annual data report. Bethesda, MD: National Institute of Diab and Dig and Kid Dis, 1989.
5. Mogensen CE, Steffes MW, Deckert T, Christiansen JS. Functional and morphological renal manifestations in diabetes mellitus. *Diabetologia* 1981;21:89-93.
6. Jong PE, Hillege HL, Joan PS, Zeeuw D. Screening for MAU in the general population: A tool to detect subjects at increased risk for progressive renal failure in an early phase. *Nephrol Dial Transpl* 2003;18:10-13.
7. Hiddo J, Heerspink L, Holtkamp F, Ravid M. Monitoring kidney function and albuminuria in patients with diabetes. *Diab Care* 2011;34:325-329.
8. N Bhavya, V Ajith Kumar. Study of Association between Microalbuminuria and Microvascular complications in type II diabetes mellitus patients in Rajarajeswari medical college and hospital, Karnataka. *J Med Sci* 2017;3(1):6-10.
9. Dick de Zeeuw, Hans-Henrik Parving and Robert H. Henning. Microalbuminuria as an Early Marker for Cardiovascular Disease. *J Am Soc Neph* 2006;17(8):2100-2105.
10. Satoru Tanaka, Hiroyuki Takase, Yasuaki Dohi, Genjiro Kimura. The prevalence and characteristics of microalbuminuria in the general population: a cross-sectional study. *BMC Res Notes* 2013;6:256-263.
11. Seema Basi, Pierre Fesler, Albert Mimran, Julia B. Lewis. Micro albuminuria in Type 2 Diabetes and Hypertension. *Diab Care* 2008;31:14.194-201.
12. Cohen MP, Chen S, Ziyadeh FN. Evidence linking glycated albumin to altered glomerular nephrin and VEGF expression, proteinuria, and diabetic nephropathy. *Kidney Int* 2005;68:1554-1556.
13. George L Bakris and Mark Molitch. Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga. *Diab Care* 2014;37:867-875.
14. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression. *Horm Metab Res* 2012;44:891-895.
15. Tourigny A, Charbonneau F, Xing P, et al. CYP24A1 exacerbated activity during diabetes contributes to kidney tubular apoptosis via caspase-3 increased expression and activation. *PLoS ONE* 2012;7:1-12
16. Patel V, Shastri M, Gaur N, Jinwala P, Kadam AY. A study in prevalence of diabetic nephropathy in recently detected cases of type 2 diabetes mellitus as evidenced by altered creatinine clearance, urinary albumin and serum creatinine, with special emphasis on hypertension, hypercholesterolemia and obesity. *Int J Adv Med* 2018;5:351-355.

**How to cite this article:** Srilakshmi P, Reddy RKYV, Bharathi PK, Rambabu K. Role of HbA1c and microalbuminuria in diabetic-hypertensive individuals: An index for the diabetic nephropathy. *Int J Clin Biochem Res* 2019;6(1):126-128.